MBAITechnology · Software - InfrastructureTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 6 of 100 as at 12 Sept 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores MBody AI Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (77): Smaller than most of the companies we track.
Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MBAI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBAI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 7% of US stocks
Cheaper than 77% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 97% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MBody AI Ltd. has a market value of $8.8M and an enterprise value of $8.8M.
Trailing P/E: 1.4×.
MBody AI Ltd. employs 85 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MBody AI Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MBody AI Ltd. announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference, holding a formal presentation and one-on-one investor meetings from September 14-16, 2026.
Why it matters — The conference gives MBody AI an opportunity to present its business to investors and engage in direct one-on-one meetings with potential stakeholders.
MBody AI Ltd. (NASDAQ: MBAI) announced the successful completion of a pilot deployment of its AI robotics at Mohegan Sun and has begun negotiations for a planned commercial expansion there.
Why it matters — A successful pilot followed by commercial-expansion talks signals progress in MBAI's AI robotics rollout and potential for a larger recurring deployment at a major venue.
MBody AI's hardware-agnostic platform has been named a finalist for the AI Deployment of the Year award, shortlisted alongside CrowdStrike, Lenovo, and CVS Health in a category recognizing real-world AI deployment.
Why it matters — Being named a finalist among major industry players highlights MBody AI's platform as a credible, recognized deployment in the enterprise AI space.
Check-Cap Ltd. announced the completion of its business combination with MBody AI Corp. on August 26, 2026, and the closing of its firm-commitment underwritten public offering of 1,538,462 ordinary shares at $6.50 per share on August 27, 2026.
Why it matters — The completion of the MBody AI merger and the closing of the underwritten offering represent significant corporate milestones for Check-Cap that advance its positioning as an embodied AI company.
Check-Cap Ltd. announced the pricing of its public offering of 1,538,462 ordinary shares at $6.50 per share, before underwriting discounts and commissions, for gross proceeds of $10 million. The offering was announced via GlobeNewsWire.
Why it matters — MBAI watchers would care because the capital raise affects the company's share count and cash position.
As at 12 Sept 2026, MBody AI Ltd. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (77 of 100).
No analyst covering MBody AI Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBAI are extrapolating price history, which says nothing about the business.
Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on capsule-based colorectal cancer screening.
The most recent item we track (GlobeNewsWire, 10 Sept 2026): "MBody AI to Present at the H.C. Wainwright 28th Annual Global Investment Conference". MBody AI Ltd. announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference, holding a formal presentation and one-on-one investor meetings from September 14-16, 2026.
Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on capsule-based colorectal cancer screening. The company develops C-Scan, an ingestible imaging capsule system designed to detect precancerous polyps and other abnormalities in the colon using a preparation-free, non-invasive approach. Its technology is intended to support earlier identification of colorectal disease while offering a more patient-friendly alternative to traditional screening methods. Check-Cap Ltd. operates in the health technology and medical devices space, serving the growing demand for accessible diagnostic tools in preventive care. The company is based in Isfiya, Israel, and its current business centers on advancing screening solutions for clinical use and broader adoption in colorectal health management.
CEO Mr. John Fowler · 85 employees · Canada · https://mbody.ai